NCT02060656Unknown2 期
A Randomised Phase II Study Comparing LEnalidomide Plus Rituximab, GEmcitabine and Methylprednisolone (LR-GEM) to Rituximab, Gemcitabine, Methylprednisolone and cisplatiN (R-GEM-P) in Second-line Treatment of Diffuse Large B-cell Lymphoma (DLBCL).
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 92
- 试验地点
- 1
- 主要终点
- Complete response rate (CRR)
研究概览
简要总结
This is a randomised, phase II open-labelled two-arm study comparing R-GEM-P and LR-GEM in second-line treatment of Diffuse Large B-cell lymphoma. Eligible patients will be randomised 1:1 between R-GEM-P and LR-GEM.
详细描述
Objectives:
Primary
To assess the complete response rate to LR-GEM (lenalidomide, rituximab, gemcitabine and methylprednisolone) and R-GEM-P (rituximab, gemcitabine,cisplatin and methylprednisolone) following 3 cycles of induction treatment as secondline therapy for patients with Diffuse Large B-cell Lymphoma.
To investigate in both arms:
- Overall response rate following 3 cycles of induction treatment evaluated by IWG 2007 criteria
- Event-free survival
- Overall survival
- Rate of successful stem cell harvest
- Toxicity
- Subgroup analyses will be performed on the primary endpoint by cell-of-origin immunohistochemical subtype using the Choi method[2] (GCB vs non-GCB), morphological subtype (centroblastic vs immunoblastic vs other), IPI (0-1 vs ³2),and previous response to treatment (£12 vs > 12 months), and eligibility for ASCT at randomisation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven CD20+ Diffuse Large B-Cell Lymphoma
- •Availability of a tumour block containing adequate histological material for central pathology review, establishment of morphological and ontogenic subtype.
- •Surgically acquired tissue samples are preferred but if core biopsy is the only suitable means by which to acquire a tissue sample then it is suggested than at least 2 cores are taken so that one can be embedded and sent for central review and one retained locally.
- •Relapsed after or refractory to one prior line of chemotherapy for DLBCL containing both rituximab and an anthracycline. Relapsed is defined as investigator assessed progression after first line treatment. Refractory is defined as patients who progressed during or who did not achieve complete remission with first line treatment (which should include radiotherapy if the patient had localised refractory disease)
- •Eligible for combination chemotherapy regimen.
- •Patient is 18 years of age on the day of signing informed consent.
- •ECOG performance status 0, 1 or
- •Baseline PET or CT scans must demonstrate FDG avid disease compatible with CT defined anatomical tumour sites.
- •Adequate bone marrow function: absolute neutrophil count (ANC) 1.0x109/l, white blood cell count 3x109/l, platelets 100x109/l, haemoglobin (Hb) 9g/dl (can be post-transfusion), unless deemed disease related
- •Adequate renal function: calculated creatinine clearance 40ml/minute.
- •Adequate liver function: serum bilirubin 1.5x ULN, ALT/AST 2.5x ULN, ALP 3x ULN (in the absence of liver metastases). If liver metastases are present, ALT, AST or ALP 5x ULN are permitted. Isolated hyperbilirubinaemia due to Gilbert's disease is acceptable.
- •Female patient of childbearing potential (FCBP) must have two negative serum β-hCG pregnancy tests at baseline.
- •FCBP agreeable to practice complete and true sexual abstinence or use two forms of contraception from 28 days prior to the period of study treatment and for 12 months after the last dose of study drugs.
- •Male patients agreeable to practice complete and true sexual abstinence or use condoms from 28 days prior to the period of study treatment and for 12 months after the last dose of study drugs.
- •Recovery from toxicity from previous anti-cancer treatment to grade 1.
排除标准
- •Documented or symptomatic central nervous system involvement or leptomeningeal disease.
- •Any other clinically significant disease or co-morbidity which may adversely affect the safe delivery of treatment within this trial, including active or chronic infection,poorly controlled diabetes mellitus, congestive cardiac failure, cardiac arrhythmia, coronary artery disease, cerebrovascular disease, or severe pulmonary disease.
- •Any other malignancies diagnosed or treated within the last 5 years (other than curatively treated basal cell or squamous cell carcinoma of the skin and/or in situ carcinoma of the cervix or breast).
- •Received drug treatment for cancer within 21 days of commencing study treatment.
- •Received previous lenalidomide
- •Evidence of human immunodeficiency virus infection, hepatitis C virus, acute or active hepatitis B infection.
- •Patient is pregnant or breastfeeding, or expecting to conceive or father children within one year of finishing study treatment.
- •Hypersensitivity or contraindication to any of the study drugs as stated in the SmPCs for each of the study drugs.
- •Prior stem cell or solid organ transplant
- •Treatment with an investigational product within 30 days prior to enrollment
- •Not able to provide fully informed consent because of intellectual impairment or psychiatric disorder
- •Patient unwilling or not able to adhere to the Lenalidomide Pregnancy Prevention Programme.
- •Treatment with combined oral contraceptive pill within 30 days prior to enrollment.
- •Treatment with hormone replacement therapy within 30 days prior to enrollment
- •Treatment with erythropoeitic agents within 30 days prior to enrollment
- •Baseline hearing impairment, which in the opinion of the investigator, may significantly worsen with treatment with cisplatin.
研究组 & 干预措施
Control: R-GEM-P
Active Comparator
Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
干预措施: Gemcitabine (Drug)
Control: R-GEM-P
Active Comparator
Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
干预措施: Methylprednisolone (Drug)
Control: R-GEM-P
Active Comparator
Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
干预措施: Rituximab (Drug)
Control: R-GEM-P
Active Comparator
Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
干预措施: Cisplatin (Drug)
Experimental: LR-GEM
Experimental
Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
干预措施: Gemcitabine (Drug)
Experimental: LR-GEM
Experimental
Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
干预措施: Methylprednisolone (Drug)
Experimental: LR-GEM
Experimental
Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
干预措施: Rituximab (Drug)
Experimental: LR-GEM
Experimental
Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
干预措施: Lenalidomide (Drug)
结局指标
主要结局
Complete response rate (CRR)
时间窗: Approximatley after 12 weeks of randomisation
次要结局
- Overall Response Rate(Approximately 12 weeks after randamisation)
- Event-free Survival(This will be calculated from the date of randomisation until the date of treatment failure up to 104 weeks)
- Rates of successful stem cell harvest(This will be calculated by the amount of stem cells collected and number of stem cell harvest attempts per patient up to 104 weeks)
- Overall Survival(this will be calculated from the date of randomisation until the date of death, irrespective of its cause.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple MyelomaMultiple MyelomaNCT01450215Karolinska University Hospital62
已完成
2 期
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway GliomaRecurrent Childhood Pilocytic AstrocytomaRecurrent Childhood Visual Pathway GliomaNeurofibromatosis Type 1NCT01553149National Cancer Institute (NCI)75
招募中
2 期
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System LymphomaPCNSLNCT04481815Second Affiliated Hospital, School of Medicine, Zhejiang University240
已完成
2 期
Lenalidomide Plus Rituxan for Untreated Mantle Cell LymphomaMantle Cell LymphomaNCT01472562Weill Medical College of Cornell University38
进行中（未招募）
不适用
A randomised study to test the effectiveness of LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) in comparison to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in treatment of Diffuse Large B-cell lymphoma (DLBCL) for the second time (when it has relapsed or grown despite the first treatment)EUCTR2012-002620-32-GBThe Royal Marsden NHS Foundation Trust92